Hospitals to Offset Cancer Drug Price Cap via Cost Cuts
Jefferies report suggests hospitals may offset the 30% margin cap on anti-cancer drugs through cost cuts and procedure price hikes.
The Indian healthcare sector is preparing to navigate a significant regulatory shift following the government's decision to cap trade margins on non-scheduled anti-cancer drugs. According to a recent report by Jefferies, hospitals may be able to mitigate the financial impact of this 30% margin cap through a combination of cost rationalisation and gradual increases in procedure prices.
The government's move, announced by the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilizers, aims to provide massive relief to patients. By capping trade margins at 30% of the Maximum Retail Price (MRP), the measure is expected to slash medicine prices by as much as 70%, potentially saving cancer patients approximately Rs 2,500 crore annually.
A Transitory Impact on Margins
While the price cap applies to a wide range of medicines—including branded, generic, domestic, imported, and both patented and non-patented drugs—the immediate effect on hospital profitability is a point of interest for investors. Jefferies suggests that while hospital margins might feel the squeeze in the short term, the impact on Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is likely to be manageable.
"Although near-term margin could be impacted, we believe this will be transitory but importantly, regulatory uncertainty eases for now," the Jefferies report stated. The brokerage noted that the period of unpredictability regarding these specific regulations has lessened, providing a clearer landscape for healthcare providers.
Lessons from the Past: Stents and Implants
To understand how hospitals might respond, the report points to historical precedents. Nearly a decade ago, the government implemented similar drastic price reductions on medical devices, such as cardiac stents and orthopaedic knee implants, which saw price drops of 70-85%.
During that period, hospitals successfully managed the financial pressure by:
- Implementing staggered increases in the prices of medical procedures.
- Executing rigorous cost rationalisation measures over a 12-to-15-month window.
- Adjusting internal cost structures to absorb the shock.
Jefferies believes that modern hospitals can draw on these lessons to protect their profitability while complying with the new anti-cancer drug regulations.
Ongoing Concerns for the Sector
Despite the easing of uncertainty regarding drug margins, the report highlights that the regulatory environment is not entirely settled. One area that remains under the microscope is the markup on medical consumables. Jefferies flagged this as a critical area for stakeholders to watch closely in the coming months.
For investors and healthcare administrators alike, the primary challenge will be balancing the government's mandate to reduce the cost burden on cancer patients with the necessity of maintaining sustainable hospital earnings. While the ability of individual hospitals to implement these cost-saving measures varies, the industry's previous experience suggests a path toward stability exists.